DALLAS — Denyse Clancy, an attorney and shareholder with the Dallas-based law firm Baron & Budd P.C., spoke at the International Mesothelioma Program's First Annual Harvard Medical School Course, “Surgery-Based Multimodality Therapy for Malignant Pleural Mesothelioma,” held in Dallas June 13-14.

The program was designed to update thoracic surgeons and other medical professionals about current diagnostic criteria and treatment options available for patients with pleural mesothelioma, a rare, asbestos-related cancer that attacks the lung's lining. It was co-sponsored by the American Association for Thoracic Surgery.

Clancy spoke with the group of medical professionals about how medical research articles are understood and applied in the courtroom — sometimes in ways not intended by the scientist authors. Her words provoked discussion among the doctors and research scientists present, including questions about the scientific community's responsibility to anticipate the legal applications of their words.

Baron & Budd has a long-standing relationship with the International Mesothelioma Program (IMP). As a member of the IMP Executive Advisory Board, the law firm is in regular contact with the IMP to remain abreast of mesothelioma research updates affecting treatment options. Baron & Budd was invited to become a member the executive board because of its experience and commitment to working with people with mesothelioma. Baron and Budd was the first and remains the longest-standing member of the IMP Executive Advisory Board.

Since 1977, Baron & Budd has championed the rights of people and communities harmed by corporate misconduct. With 49 attorneys and offices in Texas, California and Louisiana, Baron & Budd enjoys a national reputation as a leader of the plaintiffs' bar. The firm represents individuals with mesothelioma and other diseases caused by asbestos; leukemia caused by benzene; injuries caused by other toxic substances and unsafe pharmaceuticals; water authorities seeking cleanup costs for drinking water contamination; securities investors defrauded by corporate wrongdoing; and consumers in class actions.